

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Various</b>				
Cardiovascular, cancer	c-jun N-terminal kinase 3 (JNK3; MAPK10); stromal derived factor-1 (CXCL12; SDF-1)	<i>In vitro</i> studies suggest that targeting JNK3 could be useful for treating angiogenesis-associated diseases. In a capillary formation assay, small interfering RNA knockdown of JNK3 inhibited SDF-1-induced tube formation by 90.3% compared with that seen using control siRNA. Next steps include validating the results in JNK3-deficient mice and testing JNK3 inhibitors for their antiangiogenic effects. An SDF-1 antibody from RegenMed Corp., is in preclinical testing for diabetic retinopathy. NOX-A12, a chemokine inhibitor targeting SDF-1 from Noxxon Pharma AG, is in preclinical testing for the same indication.  <b>SciBX 2(13); doi:10.1038/scibx.2009.553</b> Published online April 2, 2009	Patent application filed; available for licensing from The University of North Carolina at Chapel Hill Office of Technology Development <b>Contact:</b> Kelly Sivertson, The University of North Carolina at Chapel Hill, Chapel Hill, N.C. e-mail: <a href="mailto:kelly.sivertson@unc.edu">kelly.sivertson@unc.edu</a>	Hagedorn, A. <i>et al. Science</i> ; published online March 26, 2009; doi:10.1073/pnas.0809568106 <b>Contact:</b> Cam Patterson, The University of North Carolina at Chapel Hill, Chapel Hill, N.C. e-mail: <a href="mailto:cpatters@med.unc.edu">cpatters@med.unc.edu</a>